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End-stage renal disease in Brazil: Epidemiology, prevention,
and treatment. Brazil is one of the largest and most populous
nations in the world, ranking among the 5 largest economies in
the Americas and among the 15 largest economies in the world.
However, Brazil is still plagued by social problems such as the
persistence of poverty and immense deficiencies in its health sys-
tem. Currently, there are approximately 390 patients on chronic
renal replacement therapy (RRT) per million population, about
one third the US prevalence, which suggests that end-stage renal
disease is either underdiagnosed or undertreated. The epidemi-
ology of renal disease in the small remaining native Brazilian
population is largely unknown. However, it is likely that the
prevalence of renal disease is low among at least 2 tribes: the
Yanomamis in northern Brazil and the Xingu Indians in central
Brazil. Sodium intake is very low, physical activity is intense,
and the prevalence of hypertension and cardiovascular disease
is negligible among these people, which stresses the potential
pathogenic importance of so-called civilized habits. There is cur-
rently no conclusive evidence that African descendants or any
other Brazilian ethnic minorities are especially vulnerable to
renal disease. Access to RRT in Brazil is universal. However,
because both the end-stage renal disease population and oper-
ational RRT costs are steadily increasing, the system may face
severe limitations in the near future. Much effort is needed to
limit the prevalence of renal disease, to detain or retard the
progression of chronic nephropathies, and to ensure that high-
quality RRT will remain available to all those who need it.
Resumen
Brasil es una de las naciones ma´s grandes y pobladas del
mundo. Se cuenta entre las 5 principales economı´as del con-
tinente americano y entre las 15 economı´as ma´s importantes
a nivel mundial. A pesar de lo anterior, persisten problemas
sociales tales como la pobreza y graves deficiencias en su sis-
tema de salud. Existen actualmente cerca de 390 pacientes por
millo´n de habitantes en terapia de reemplazo, un 30% de lo
reportado en los Estados Unidos de Ame´rica, indicando que
la insuficiencia renal cro´nica (IRC) no se diagno´stica o no es
tratada en todos los casos. La epidemiologı´a de la IRC en la
escasa poblacio´n nativa brasilen˜a se desconoce. Sin embargo,
es de esperar que su prevalencia sea baja, al menos en las etnias
Yanomami en el norte del paı´s y los Xingu en la parte central. La
ingesta de sal es baja, la actividad fı´sica es intensa y la prevalen-
cia de hipertensio´n arterial y enfermedades cardiovasculares es
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casi nula en esta poblacio´n, poniendo de manifiesto los riesgos
de los denominados ha´bitos civilizados. Por otra parte, no existe
evidencia de que la poblacio´n de ascendencia africana u otra et-
nia brasilen˜a presenten un mayor riesgo de padecer enfermedad
renal. El acceso a las terapias de reemplazo de la falla renal es
universal. Sin embargo, el constante incremento en el nu´mero
de pacientes y en los costos del tratamiento, ocasionara´n lim-
itaciones en el sistema en un futuro cercano. Se requiere de un
gran esfuerzo para limitar la prevalencia de enfermedad renal y
retardar o detener la progresio´n de las nefropatı´as cro´nicas, ası´
como el garantizar que terapias de reemplazo de alta calidad
continu´en disponibles para todos aquellos que lo necesiten.
DEMOGRAPHIC DATA
Brazil is the fifth largest nation in the world, occupy-
ing nearly half of the total continent area and holding an
equal proportion of the population of the South Amer-
ican subcontinent. Most of the more than 170 million
Brazilians live in urban areas, mainly by the eastern and
southeastern coasts, where most industrial activities and
services are concentrated.
From an ethnic point of view, almost 60% of the Brazil-
ian population is Caucasian, descending from the Por-
tuguese colonizers and, to a lesser degree, from Euro-
pean immigrants. African descendants, mostly mulattos,
represent the second major ethnic group (although the
high degree of race mixing makes it frequently difficult
to discern between mulattos and Caucasians), whereas
Asian and Semitic descendants constitute small minori-
ties totaling about 1% of the population. Native Indians,
who numbered in several millions at the time Brazil was
discovered by the Portuguese, currently represent a very
small minority of less than 0.5% of the total population;
they are distributed among myriads of tribes, which are
scattered mostly around the central and northern regions,
some of whom have never had contact with civilization.
As in other countries, life expectancy has increased, now
reaching 69 years at birth, and 75 years at 40 years of age
[1].
Although Brazil’s economy ranks among the 15 largest
economies in the world, its per capita income, around
US $7000 (according to the purchasing power parity
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concept), is that of an “intermediary” nation. Brazil
exhibits some characteristics typically found in developed
countries—a predominantly urban population, large-
scale mechanized farming, a well-developed industrial
infrastructure, and a steady increase in the weight of ser-
vices in the economy. However, despite some improve-
ments observed in the last decades, Brazil is still plagued
by problems more readily associated with poor countries,
such as severe deterioration of some urban areas, poor
educational indices, and high infant mortality rate.
PREVALENCE OF RENAL DISEASE
There are little data on the prevalence of renal dis-
ease in Brazil. In a recent survey of a small inland city of
southeastern Brazil [2], 0.5% of the adult (18–59 years)
and 5.1% of the older adult (>60 years) population were
found to have elevated serum creatinine levels, whereas
the prevalence of hypertension was 20% and 60%, re-
spectively. If these percentages were to be extrapolated
to the overall Brazilian population, considering its age
composition, the total number of people who have renal
insufficiency could be roughly estimated at 1.2 million.
These figures may be underestimated, however, because
those patients with more advanced renal failure may have
either migrated to larger cities in which complex medical
procedures were more readily available, or succumbed
without ever being diagnosed due to lack of adequate
local medical attention.
Although national registries on renal disease are still
incomplete, it is clear from epidemiologic evidence ob-
tained in the past decade that primary glomerulopathies
constitute a persistent cause of chronic nephropathy in
Brazil; these account for nearly 20% of all registered
cases of end-stage renal disease (ESRD) between 1997
and 2000 [3–5]. Focal segmental glomerulosclerosis and
membranous glomerulonephritis are the leading modali-
ties of glomerulopathy, although the importance of im-
munoglobulin A nephropathy has increased in recent
years, according to 2 recent biopsy-based studies [6, 7].
Although its occurrence may have declined in larger
urban areas in recent years, postinfectious glomeru-
lonephritis may also have an unsuspected importance
as a cause of ESRD, given the recent occurrence of an
outbreak in a rural area [8], with some cases evolving
to progressive nephropathies. Other nephropathies asso-
ciated with poor hygienic conditions, such as glomeru-
lopathy secondary to schistosomiasis, are relatively less
important as causes of ESRD [9]. In a recent report, hy-
pertensive nephrosclerosis and diabetes were causes of
ESRD in 24% and 14% of patients, respectively [5]. This
pattern, which is similar to that of other Latin Ameri-
can countries [10], contrasts with that observed in the
United States, where diabetic nephropathy and hyper-






Fig. 1. Distribution of causes of ESRD among new patients on chronic
dialysis in Brazil.
quarters of the population on chronic dialysis [11]. These
discrepancies, which can be partially explained by the
larger proportion of elderly people, characteristic of de-
veloped countries, may be decreasing: diabetes had been
considered a cause of ESRD in only 8% of cases in the
mid-1990s [3, 4], as opposed to 14% between 1997 and
2000 [5]. Additionally, recent data from the Ministry of
Health showed that hypertension and diabetes were the
presumed cause of ESRD among patients newly admit-
ted to chronic dialysis in 26% and 18% of cases, respec-
tively, whereas glomerulonephritis corresponded to only
11%. Similar figures were obtained from a group of 247
predialysis patients in our service (Fig. 1).
Although acute renal failure in Brazil is most frequent
among critically ill patients, its pattern may also be con-
ditioned by socioeconomic factors. Acute renal failure
often follows accidents with poisonous animals such as
snakes, spiders, bees, and caterpillars in rural areas [12],
or exposure to infectious agents, such as in leptospirosis
(in urban flooded areas), malaria (in the vicinity of the
Amazon rainforest), and tetanus [12].
RENAL DISEASE AMONG MINORITIES
The high degree of race mixing in Brazil makes it diffi-
cult to perform a quantitative analysis of the influence of
ethnic factors on renal disease. The few studies address-
ing the subject provide no evidence of the importance of
these factors, although a few suggest that, as in the United
States, the prognosis of chronic renal disease tends to be
worse in African [13] and Asian [14] descendants.
Unlike in other countries of Central and South
America, the Native Indian population and their de-
scendants amount to only a few hundred thousand, scat-
tered throughout the Brazilian territory, especially in the
northern and central regions. Epidemiologic data on the
prevalence of renal disease in these populations are very
scarce. A recent analysis of the International Study of
Salt and Blood Pressure [15], which involved 52 different
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populations from 4 continents, included 2 native Brazilian
communities: the Yanomami Indians, who live in north-
ern Brazil and southern Venezuela, and the Xingu In-
dians, who live in central Brazil. Both communities have
extremely low urinary sodium excretion rates in compari-
son with those of other populations. In fact, sodium excre-
tion rates among the Yanomamis (0.9 mmol/day on aver-
age) were the lowest ever reported in the literature. Low
sodium excretion (6 mmol/day on average) was also ob-
served in the Xingu Indians and in 2 additional communi-
ties outside Brazil, in Papua New Guinea (27 mmol/day)
and in Kenya (51 mmol/day), whereas the average value
for the remaining 48 centers was 160 mmol/day. In addi-
tion, Yanomamis had high potassium intake, consumed
no alcohol, and were physically active, although this was
not quantified. No obesity was seen among Yanomamis.
Body mass index varied between 20.8 and 23.4 kg/cm2
among the 4 low-salt intake communities, compared with
25.2 kg/cm2 in the remaining communities. Blood pres-
sure showed a strong correlation with sodium excretion
rates, even when only the 4 low-salt intake communities
were considered. No increase in blood pressure with age
occurred in the latter. Renal diseases were not studied in
these populations, although it is reasonable to suppose
that their prevalence is equally low. Both sodium intake
and prevalence of hypertension increase with accultura-
tion [16], which reinforces the notion that hypertension,
as well as cardiovascular and renal diseases, may largely
be consequences of “civilized” habits.
RENAL REPLACEMENT THERAPY
About 18,000 new patients with ESRD, correspond-
ing to approximately 104 patients per million population
(pmp), begin chronic dialysis (mostly hemodialysis) every
year in Brazil [5]. There are currently an estimated 70,000
patients (approximately 390 pmp) on chronic dialysis in
the country. Corresponding figures in countries such as
Japan and the US are 1400 pmp and 1100 pmp, respec-
tively [17], which suggests that ESRD may be either un-
derdiagnosed or undertreated (or both) in Brazil. The
population of patients who have undergone transplanta-
tion, currently estimated at 22,000 (125 pmp), represents
only 24% of the total RRT population, as opposed to
50% in Denmark, 40% in France, and 43% in Canada
[17]. The National Transplant System (linked to the Min-
istry of Health) has local branches in several states and is
responsible for organ procurement and allocation. There
is currently a waiting list of more than 25,000 patients,
up from 4000 in 1992. About 3000 renal transplants per
year (approximately 17 ppm) are currently performed in
Brazil, as opposed to 46 pmp in the United States and 41
pmp in Sweden. This corresponds to only 30% of the total
that is necessary to stabilize the waiting list [17]. About
40% of the transplanted kidneys are currently obtained
from living donors, as opposed to 10% in Europe and
30% in the United States.
Despite Brazil’s socioeconomic limitations, access to
health services, including the latest-generation medical
procedures and treatments, has been guaranteed by law
to all those who have sought them in the past 30 years.
Nephrology, which gained the status of a medical dis-
cipline as early as 1960, has become a well-established
specialty. There are now nearly 18 nephrologists pmp,
which corresponds to approximately 1 nephrologist per
55,000 inhabitants. The Brazilian Society of Nephrology
has more than 2000 registered members, whereas RRT
centers exist virtually throughout the entire Brazilian ter-
ritory, comprising 561 dialysis and 143 renal transplant
units, mostly concentrated in the more prosperous coastal
areas, particularly in the southeast region. The vast ma-
jority of Brazilian dialysis units use proportion machines
and polysulphon or cellulose acetate dialyzers, whereas
federal regulation limits reuse and requires reverse os-
mosis for the treatment of water. The government also
provides immunosuppressors, antibiotics, and other med-
ication necessary for the maintenance of patients who
have undergone transplantation. The quality of RRT ser-
vices is comparable with that of developed countries:
yearly mortality is currently less than 15% for patients
on chronic dialysis [5] and less than 4% for patients who
have undergone transplantation [18]. The current preva-
lence of hepatitis B infection among patients on chronic
dialysis is slightly above 3%, whereas hepatitis C virus
occurs in about 15% of these patients [5]. The use of ad-
vanced prevention and isolation techniques has lowered
the incidence of both hepatitis B and hepatitis C viruses
in recent years.
Based on available statistics, the dynamics of
ESRD/RRT in Brazil can be estimated according to the
scheme depicted in Figure 2. Examination of this figure
shows that the total amount of patients on chronic dial-
ysis is currently increasing at a rate of about 7000 per
year. This would predict stabilization of the system in 10
years at approximately 120,000 patients on chronic dialy-
sis. However, stabilization may take much longer and the
number of patients on RRT may become much higher as
an increasing fraction of the destitute population gains ac-
cess to adequate medical attention. Thus, there is a clear
need for preventive measures, including early detection
of chronic nephropathies, strict treatment of diabetes and
hypertension, and the development of more effective pro-
cedures than currently available to retard progression to
ESRD.
FUNDING OF RRT
RRT in Brazil is funded mostly by the Ministry of
Health (MH), with less than 5% of the procedures be-
ing covered by private or corporate health insurance. The
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Fig. 2. Dynamics of RRT in Brazil.
MH pays approximately US $37 per hemodialysis session
including medical fees, whereas continuous ambulatory
peritoneal dialysis costs approximately US $480 per pa-
tient per month. Altogether, the yearly direct expenses
with RRT amount to approximately US $400 million,
of which US $300 million are assigned to dialysis (ap-
proximately US $4300 per patient per year) and US $100
million to patients who have undergone transplantation.
In addition, the MH provides the primary drugs used in
the treatment of these patients, such as recombinant ery-
tropoietin, calcitriol, sevelamer, antihypertensive drugs,
and hepatitis B vaccination and, for patients who have
undergone transplantation, the standard triple therapy
(cyclosporine, azathioprine, and steroids) and, more re-
cently, mycophenolate mofetil (MMF), rapamycin, and
tacrolimus (FK-506). The MH also pays for the trans-
plantation procedure (approximately US $4000, includ-
ing medical fees). The government’s ability to finance
these expenses has been limited in recent years, because
funds assigned to RRT have remained constant in the
face of an unfavorable currency exchange rate and an
ever-increasing ESRD population, which further stresses
the need for preventive measures.
CONCLUSION
As in other emerging countries, glomerulonephritis is
still a common cause of ESRD in Brazil, although the
importance of diabetes and hypertension appears to be
increasing. There is currently little solid evidence that
the prevalence of ESRD is higher, or that its prognosis is
worse, in African descendants or other minorities. Infor-
mation on renal disease among native Brazilians is even
scarcer, although there is evidence that hypertension, and
possibly renal disease, are rare among at least some tribes,
in association with low salt intake, alcohol abstinence, and
a high degree of physical activity. The ESRD population
is steadily increasing in Brazil, imposing growing costs
to the health system. The real prevalence of renal disease
may be underestimated because of limited access to med-
ical attention for a substantial fraction of the population.
RRT is funded mostly by the Brazilian government, pro-
viding the ESRD population with access to sophisticated
medicines and procedures. However, growing costs in the
face of limited resources may shortly jeopardize the sys-
tem. As in most countries, measures for the prevention,
early diagnosis, and treatment of chronic nephropathies
are urgently needed.
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